Most Read Articles
Fiel Soliven, 01 Apr 2015
The effects canagliflozin on serum acid levels of type 2 diabetes mellitus patients and a subset who have hyperuricaemia were assessed in this review article.
16 Jun 2016
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
Elvira Manzano, 30 Oct 2015
Hyperbaric oxygen therapy improves long-term survival in patients with chronic diabetic foot ulcers, according to 6-year follow-up data from the HODFU* study.
15 Jun 2016
Bicalutamide plus everolimus is a promising treatment for patients with castration-resistant prostate cancer (CRPC), based on a phase II clinical trial.

Improving the success of in vitro fertilization and overcoming male factor infertility with intracytoplasmic morphologically selected sperm injection

01 Jun 2014
Dr Nicolas Zech talks about improving the success of in vitro fertilization and overcoming male factor infertility with intracytoplasmic morphologically selected sperm injection
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Fiel Soliven, 01 Apr 2015
The effects canagliflozin on serum acid levels of type 2 diabetes mellitus patients and a subset who have hyperuricaemia were assessed in this review article.
16 Jun 2016
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
Elvira Manzano, 30 Oct 2015
Hyperbaric oxygen therapy improves long-term survival in patients with chronic diabetic foot ulcers, according to 6-year follow-up data from the HODFU* study.
15 Jun 2016
Bicalutamide plus everolimus is a promising treatment for patients with castration-resistant prostate cancer (CRPC), based on a phase II clinical trial.